Company Filing History:
Years Active: 2019
Title: Ellen Qiao Wang: Innovator in Therapeutic Dosing Regimens
Introduction
Ellen Qiao Wang is a notable inventor based in Brooklyn, NY (US). She has made significant contributions to the field of medicine, particularly in the development of therapeutic strategies for managing cholesterol levels.
Latest Patents
Ellen holds a patent for a treatment involving anti-PCSK9 antibodies. This invention focuses on therapeutic dosing regimens that utilize a dose reduction strategy for treating disorders characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels in patients. The patent outlines a method of delivering an initial dose of at least about 100 mg of an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody, followed by subsequent doses that may be equal to or at least half of the initial dose, depending on the patient's LDL-C levels.
Career Highlights
Ellen is currently employed at Pfizer Corporation, a leading global pharmaceutical company. Her work at Pfizer has allowed her to focus on innovative treatments that address critical health issues related to cholesterol management.
Collaborations
Ellen collaborates with Anne Barbara Cropp, who is also a prominent figure in the field. Their partnership exemplifies the importance of teamwork in advancing medical research and innovation.
Conclusion
Ellen Qiao Wang's contributions to therapeutic dosing regimens highlight her role as an innovator in the medical field. Her patent for treating elevated LDL-C levels demonstrates her commitment to improving patient outcomes through scientific advancements.